Pfizer Ltd - Stock Valuation and Financial Performance

BSE: 500680 | NSE: PFIZER | Pharmaceuticals & Drugs | Small Cap

Pfizer Share Price

4,872.90 -77.30 -1.56%
as on 12-Jul'24 16:01

DeciZen - make an informed investing decision on Pfizer

Overall Rating
Bole Toh

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Pfizer stock performance -

mw4me loader
P/E Ratio (SA):
40.26
Market Cap:
22,196.1 Cr.
52-wk low:
3,731.1
52-wk high:
5,050

Is Pfizer Ltd an attractive stock to invest in?

1. Is Pfizer Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Pfizer Ltd is a good quality company.

2. Is Pfizer Ltd undervalued or overvalued?

The key valuation ratios of Pfizer Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Pfizer Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Pfizer Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Pfizer:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Pfizer Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 18.8%12%14.2%10.6%13.9%14.4%15.5%17.4%23.5%20%-
Value Creation
Index
0.3-0.10.1-0.20.00.10.20.61.10.5-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1,1121,8532,0121,9661,9692,0822,1522,2392,6112,4252,193
Sales YoY Gr.-66.7%8.6%-2.3%0.1%5.7%3.4%4%16.6%-7.1%-
Adj EPS 73.734.363.952.977.789.4106.8108133.4131120.5
YoY Gr.--53.5%86.4%-17.3%46.9%15.1%19.5%1.1%23.5%-1.8%-
BVPS (₹) 220.6431.3472.9528.7586.5658.2742.2523.1626.1701.1786
Adj Net
Profit
220157292242355409489494610599551
Cash Flow from Ops. 13211334532933297.8323427667356-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 9.1%4.3%4.1%-7.1%
Adj EPS 6.6%11%7%-1.8%
BVPS13.7%3.6%-1.9%12%
Share Price 13.7% 9% -5.3% 28.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
18.711.914.110.613.914.415.317.123.219.716.2
Op. Profit
Mgn %
21.620.621.617.825.527.326.931.832.133.429
Net Profit
Mgn %
19.88.514.512.318.119.722.722.123.424.725.1
Debt to
Equity
00000000000
Working Cap
Days
169143158150162182195194169182211
Cash Conv.
Cycle
2120-1-10-40-27-462023165

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 16.20%

Sales growth has been subdued in last 3 years 4.06%

Net Profit has been subdued in last 3 years 7.02%

Sales growth is not so good in last 4 quarters at -9.46%

Latest Financials - Pfizer Ltd.

Standalone Consolidated
TTM EPS (₹) 120.5 30
TTM Sales (₹ Cr.) 2,193 772
BVPS (₹.) 786 0
Reserves (₹ Cr.) 3,550 965
P/BV 6.17 0.00
PE 40.26 161.87
From the Market
52 Week Low / High (₹) 3731.05 / 5050.00
All Time Low / High (₹) 27.50 / 6164.80
Market Cap (₹ Cr.) 22,196
Equity (₹ Cr.) 45.8
Face Value (₹) 10
Industry PE 43.9

Management X-Ray of Pfizer:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Pfizer

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales1,1121,8532,0121,9661,9692,0822,1522,2392,6112,425
Operating Expenses 8731,4741,5791,6161,4681,5161,5791,5261,7751,616
Manufacturing Costs133173164162131143116130138129
Material Costs306650699712678678742734876803
Employee Cost 192236277304314324365361404332
Other Costs 242415439439345370357301358352
Operating Profit 239379433350501566573712836809
Operating Profit Margin (%) 21.5%20.5%21.5%17.8%25.4%27.2%26.6%31.8%32.0%33.4%
Other Income 10972871011141671848163101
Interest 12121211151113
Depreciation 813158636671103109115106
Exceptional Items 0-80101300000033
Profit Before Tax 340238470517548660642669773824
Tax 119138165180188231133171160200
Profit After Tax 221100305337360429509498613624
PAT Margin (%) 19.9%5.4%15.2%17.1%18.3%20.6%23.7%22.2%23.5%25.7%
Adjusted EPS (₹)74.021.966.773.678.793.8111.3108.8133.9136.4
Dividend Payout Ratio (%)486%57%23%27%25%24%297%32%22%51%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 6581,9732,1632,4192,6833,0113,3952,3932,8643,207
Share Capital 30464646464646464646
Reserves 6291,9272,1182,3732,6372,9663,3502,3472,8193,162
Minority Interest0000000000
Debt0333333333
Long Term Debt0330000000
Short Term Debt0003333333
Trade Payables160334338388496436427284264217
Others Liabilities 124237384452509490580573723476
Total Liabilities 9422,5472,8883,2613,6903,9404,4053,2523,8543,903

Fixed Assets

Gross Block1151,2899819831,0951,1001,2771,2791,3451,352
Accumulated Depreciation9534456116178246335414504603
Net Fixed Assets20944925867917854942865841749
CWIP 313315101318
Investments 444300000000
Inventories151388361322297387431435449418
Trade Receivables173160142110155172172109143152
Cash Equivalents 3086091,0251,5231,7721,9142,2201,1151,6431,860
Others Assets242390432423549613640726777717
Total Assets 9422,5472,8883,2613,6903,9404,4053,2523,8543,903

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 13211334532933298323427667356
PBT 340238470517548660642669773824
Adjustment -8861-20-154-33-79-545576-131
Changes in Working Capital 5-406914910-245-52-9244-34
Tax Paid -124-145-174-183-194-238-213-204-226-303
Cash Flow From Investing Activity 103-89-701-250-238351,530-469-575-36
Capex -2-2053169-6927-2-18-13-64
Net Investments 00-833-502000-502-613-229
Others 105-697984-16981,5325151257
Cash Flow From Financing Activity -1,360-1-62-83-110-110-164-1,571-181-346
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid 0000000-3-11-13
Dividend Paid -1,161-1-50-69-92-91-103-1,519-160-297
Others -1990-12-14-19-19-60-49-10-35
Net Cash Flow -1,12523-417-3-17231,690-1,613-88-26
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)18.777.6314.7514.714.1115.0715.8917.1923.320.55
ROCE (%)28.9618.1922.7822.6221.4923.2220.3823.6229.7827.56
Asset Turnover Ratio0.791.10.770.660.570.550.520.580.760.66
PAT to CFO Conversion(x)0.61.131.130.980.920.230.630.861.090.57
Working Capital Days
Receivable Days49322623242929231721
Inventory Days50516561576069715962
Payable Days186139176186238251212177114109

Pfizer Ltd Stock News

Pfizer Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Pfizer on 12-Jul-2024 16:01 is ₹4,872.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Jul-2024 16:01 the market cap of Pfizer stood at ₹22,196.1.
The latest P/E ratio of Pfizer as of 12-Jul-2024 16:01 is 40.26.
The latest P/B ratio of Pfizer as of 12-Jul-2024 16:01 is 6.17.
The 52-week high of Pfizer is ₹5,050 and the 52-week low is ₹3,731.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Pfizer is ₹2,193 ( Cr.) .

About Pfizer Ltd

Pfizer is a Public Limited Company, incorporated under the Indian Companies Act, 1913, having its registered office in Mumbai, Maharashtra and is listed on the BSE Limited and the National Stock Exchange of India Limited

Pfizer scientists have produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections. The company is taking on some of the world's most difficult diseases, including cancer, arthritis, and osteoporosis.

Business area of the company

Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.

Awards

2001

  • OPPI Brand Excellence Award for Minipress XL.

2002

  • Express Pharma Biz Award for overall performance.
  • Rated as one of India's most socially responsive companies. Awarded by FICCI-Socio Economic Development Foundation for our Social Responsiveness.

2003

  • Voted as the 5 'Most Respected Company' in the Pharma sector (Business World).
  • Corporate Advertising Campaign won a Silver Award at the ABBY-All India Awards for Creative Excellence. Gelusil brand received a Silver Award for printing advertising.
  • Golden Peacock National Training Special Commendation for Training practices.

2004

  • Ranked 5 among all pharmaceutical companies, with respect to corporate image, field-force, and promotional programs (AC Nielsen-ORG Marg 'Corporate Image Survey').
  • Ranked 1 among all Pharma MNCs & 4 among all Pharma Companies by Business World.
  • Kewal Handa, CFO Pfizer Limited receives the ‘India CFO 2004 - Excellence in Finance in an MNC’ by International Market - Assessment Group.

2005

  • Golden Peacock Innovative Service Award for Prime MD Today (Daxid).
  • PC Quest 'Best IT Implementation Users Choice' award for OPTILEARN.
  • Pharma Excellence Awards 2006 in 'Innovative Products of the Year' category for Exubera.
  • Ranked 1 among multinationals and #3 among all pharmaceuticals, in the Business World survey.

2006

  • Pharma Excellence Awards 2006 in 'Innovative Products of the Year' category for Exubera.
  • Ranked 1 among multinationals and 3 among all pharmaceuticals, in the Business World survey.
  • Kewal Handa, Managing Director Pfizer, awarded the Bharat Shiromani award for his outstanding contribution in the pharmaceutical industry.

2007

  • Reader’s Digest Trusted Brand Asia - Gold Award 2007’ in the vitamin and health supplement category for Becosules.

2008

  • Frost & Sullivan Brand Strategy Leadership Award for Becosules in the Indian Dietary Supplement Market.
  • Pfizer India was recently conferred the ‘Innovative Training Practices’ Award for promoting effective and optimum utilization of human resource through education and training by the Indian Society for Training and Development (ISTD).

2009

  • Pfizer Limited (India) conferred the Multinational Pharmaceutical Company of the Year by Frost & Sullivan.

2010

  • Pfizer Limited awarded the Most Admired Pharmaceutical Company of the Year by Pharma Leaders Magazine.
  • Kewal Handa, Country Manager - Pfizer Limited recognized as Pharma Professional of the Year by Pharma Leaders Magazine.
  • Pfizer wins the Community Engagement Award at the Asia Responsible Entrepreneurship Awards 2010 in India.

2011

  • Pfizer India has been recognized as one of The Best Companies to Work For by Business Today magazine.

2012

  • J.D. Power and Associates has honored the MS LifeLines call center with certification for an outstanding customer service experience. This is the first time J.D. Power has recognized a pharmaceutical call center. Click Here.

2013

  • GBCHealth Business Leadership Award - in recognition for the Global Health Fellows program. This award is given annually to a company or business leader with a deep and long-term commitment to global health that extends beyond the business objective of the company itself. Caroline Roan will be accepting the award on behalf of Pfizer.
  • Business Action on Health Award in Application of Core Competence for Global Health Fellows Program (commendation). Oonagh Puglisi will be accepting the award for the GHF program.
  • Business Action on Health Award in Partnership/Collective Action for Advancing Cancer & Tobacco Control in China Program. Danlong Feng, Corporate Affairs Director, Pfe China, will be accepting the award.
  • QUESTAR Award - The International Awards Festival for Excellence in Video Communications Pfizer was awarded the Grand -- best of category -- in Annual Reports in the 2013 Questar Awards.
  • Telly Award - For over a quarter century, the Telly statuette has been a symbol of creative excellence. Pfizer was awarded - Bronze at the 2013 Telly's for online videos.

Milestones:

  • 1849: Charles Pfizer & Company established. 1' product for treatment of intestinal worms is a success.
  • 1880: Pfizer manufactures Citric Acid. Rapid growth on the back of aerated drinks demand.
  • 1882: Alexander Fleming discovers penicillin.
  • 1944: Pfizer finds a way to mass-produce Penicillin.
  • 1950: Terramycin, the 1st pharmaceutical sold in the US under the Pfizer label.
  • 1950: India operation launched, with HQ in Mumbai.
  • 1966: Pfizer listed on the Bombay Stock Exchange.
  • 1989: Dolonex (Feldene) launched in India.
  • 1993: Amlogard (Norvasc) launched in India.
  • 1996: Launch of MinipressXL, an anti hypertensive drug.
  • 1998: Launch of Viagra, for erectile dysfunction.
  • 1999: Pfizer listed on the National Stock Exchange.
  • 2000: Launch of Magna& a unique hospital antibiotic.
  • 2002: Futuristic tablet manufacturing Goa plant commissioned in a record 13 months.
  • 2003 Completes merger with Parke-Davis (India) Ltd.
  • 2005: Announces merger with Pharmacia Healthcare ltd.
  • 2006: Launch of LYRICA (pregaballn for treatment of neuropathic pain)
  • 2008: Launch of Champix - a non-nicotine smoking cessation prescription drug.
  • 2010: Launch of Prevenar 13, vaccine for prevention of pneumococcal disease and included later in India’s Universal Immunization Programe.
  • 2015: Completed merger with Wyeth Limited.
  • 2016: Launched Xeljanz-the first oral Janus Kinase (JAK) inhibitor.
  • 2017: Acquires 2 breakthrough brands- Meronem, Neksium.
  • 2019: Reorganizes into 3 distinct business units: Pfizer Biopharma Group, UpJohn and Consumer Healthcare. New purpose and values unveiled.
  • 2019: Launches novel anti-bacterial Zavicefta in India.
  • 2020: Launch of Zinforo, a noval cephalosporin indicated for treatment of adult patients with community- acquired Pneumonia.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.